A Novel Functional Imaging Technique With FLT-PET/MRI For Staging, Response Assessment and Radiation Treatment Planning in Cervix Cancer

National Cancer Centre, Singapore

Status

Unknown

Conditions

Image, Body

Cervix Cancer

Treatments

Diagnostic Test: [18F]FLT-PET/MRI body scan

Study type

Interventional

Funder types

Other

Identifiers

NCT05355558

LEGEND19

Details and patient eligibility

About

This pilot study aims to monitor early tumour response based on [18F]FLT-PET/MRI scans and to determine the feasibility of personalised radiotherapy to spare active bone marrow areas identified by [18F]FLT-PET/MRI. Bone marrow within the pelvis will be outlined by employing 18FLT PET to identify active BM within bony structures. Subsequently, treatment plans with various conformal radiotherapy techniques will be generated with different optimization approaches toward bone marrow while ensuring adequate tumor coverage.

Dosimetric comparison amongst plans will be carried out.

Enrollment

15 estimated patients

Sex

All

Ages

21 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have given written informed consent, with the understanding that consent may be withdrawn at any time without prejudice
Histologically or cytologically confirmed cervical carcinoma
FIGO staged IB to IVA
Underwent MRI pelvis
Underwent FDG-PET/CT or MRI abdomen or CT thorax and abdomen or Chest X ray for routine staging
Planned for radical radiotherapy with or without chemotherapy
No distant metastasis in staging work up
ECOG 0-2
Age 21 or over (no upper age limit)

Exclusion criteria

Patients scheduled for neoadjuvant chemotherapy
Patients with previous hysterectomy or radiotherapy to the pelvis
Patients who are pregnant or lactating
Patients who do not meet the above mentioned inclusion criteria
Patients who refuse to give and/or sign the informed consent
Patients who currently have a pacemaker
Patients who have a history of serious adverse events related to a previous MRI or PET/CT
Patients who are unable to undergo MRI scanning
Patients with a known allergy against any component of the contrast enhancing agent
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule; these conditions should be discussed with the patient before registration in the trial.